نتایج جستجو برای: protective antigen pa

تعداد نتایج: 345007  

Journal: :Infection and immunity 2004
Hadar Marcus Rachel Danieli Eyal Epstein Baruch Velan Avigdor Shafferman Shaul Reuveny

Protective antigen (PA)-based vaccination is an effective countermeasure to anthrax infection. While neutralizing anti-PA antibody titers elicited by this vaccine serve as good correlates for protection against anthrax (S. Reuveny, M. D. White, Y. Y. Adar, Y. Kafri, Z. Altboum, Y. Gozes, D. Kobiler, A. Shafferman, and B. Velan, Infect. Immun. 69:2888-2893, 2001), no data are available on the co...

2009
Ronit Rosenfeld Hadar Marcus Einat Ben-Arie Bat-El Lachmi Adva Mechaly Shaul Reuveny Orit Gat Ohad Mazor Arie Ordentlich

Several studies have demonstrated that the passive transfer of protective antigen (PA)-neutralizing antibodies can protect animals against Bacillus anthracis infection. The standard protocol for the isolation of PA-neutralizing monoclonal antibodies is based upon a primary selection of the highest PA-binders by ELISA, and usually yields only few candidates antibodies. We demonstrated that by ap...

2014
Lina Hao Feng Zheng Siping Xiong Dan Hu Heng Lv Qi Tang Jin Yang Zhenqing Feng Changjun Wang Jin Zhu

The aim of this research is to develop a human/murine chimeric Fab antibody which neutralizes the anthrax toxin, protective antigen (PA). The chimeric Fab was constructed using variable regions of murine anti-PA monoclonal antibody in combination with constant regions of human IgG. The chimeric PA6-Fab was expressed in E. coli. BL21 and evaluated by ELISA and co-immunoprecipitation- mass spectr...

Journal: :Vaccine 2011
Jyotsna Gorantala Sonam Grover Divya Goel Amit Rahi Sri Krishna Jayadev Magani Subhash Chandra Rakesh Bhatnagar

The currently available anthrax vaccines are limited by being incompletely characterized, potentially reactogenic and have an expanded dosage schedule. Plant based vaccines offer safe alternative for vaccine production. In the present study, we expressed domain IV of Bacillus anthracis protective antigen gene [PA(dIV)] in planta (by nuclear agrobacterium and chloroplast transformation) and E. c...

Journal: :The Journal of Experimental Medicine 2005
Silvia Rossi Paccani Fiorella Tonello Raffaella Ghittoni Mariarita Natale Lucia Muraro Mario Milco D'Elios Wei-Jen Tang Cesare Montecucco Cosima T. Baldari

Anthrax is an infection caused by pathogenic strains of Bacillus anthracis, which secretes a three-component toxic complex consisting of protective antigen (PA), edema factor (EF), and lethal factor (LF). PA forms binary complexes with either LF or EF and mediates their entry into host cells. Although the initial phases of bacterial growth occur in the lymph node, the host fails to mount an eff...

Journal: :Proceedings of the National Academy of Sciences of the United States of America 2010
Mazdak Radjainia Jae-Kyung Hyun Clinton E Leysath Stephen H Leppla Alok K Mitra

The tripartite protein exotoxin secreted by Bacillus anthracis, a major contributor to its virulence and anthrax pathogenesis, consists of binary complexes of the protective antigen (PA) heptamer (PA63h), produced by proteolytic cleavage of PA, together with either lethal factor or edema factor. The mouse monoclonal anti-PA antibody 1G3 was previously shown to be a potent antidote that shares F...

Journal: :Biochemical and biophysical research communications 1991
S F Little J R Lowe

The pag gene, which codes for protective antigen (PA), a common component of the lethal and edema toxins of Bacillus anthracis, was cloned and expressed in Escherichia coli. Nested deletions of pag were generated into the C-terminus coding region. Recombinant proteins were analyzed by Western blot with either an anti-PA polyclonal antisera or two monoclonal antibodies that neutralized lethal to...

2002
Conrad P. Quinn Vera A. Semenova Cheryl M. Elie Sandra Romero-Steiner Carolyn Greene Han Li Karen Stamey Evelene Steward-Clark Daniel S. Schmidt Elizabeth Mothershed Janet Pruckler Stephanie Schwartz Robert F. Benson Leta O. Helsel Patricia F. Holder Scott E. Johnson Molly Kellum Trudy Messmer W. Lanier Thacker Lilah Besser Brian D. Plikaytis Thomas H. Taylor Alison E. Freeman Kelly J. Wallace Peter Dull Jim Sejvar Erica Bruce Rosa Moreno Anne Schuchat Jairam R. Lingappa Sandra K. Martin John Walls Melinda Bronsdon George M. Carlone Mary Bajani-Ari David A. Ashford David S. Stephens Bradley A. Perkins

The bioterrorism-associated human anthrax epidemic in the fall of 2001 highlighted the need for a sensitive, reproducible, and specific laboratory test for the confirmatory diagnosis of human anthrax. The Centers for Disease Control and Prevention developed, optimized, and rapidly qualified an enzyme-linked immunosorbent assay (ELISA) for immunoglobulin G (IgG) antibodies to Bacillus anthracis ...

2017
CF Nagy J Mondick N Serbina LS Casey SE Carpenter J French R Guttendorf

Obiltoxaximab, a monoclonal antibody against protective antigen (PA), is approved for treatment of inhalational anthrax under the US Food and Drug Administration's (FDA) Animal Rule. The human dose was selected and justified by comparing observed obiltoxaximab exposures in healthy and infected New Zealand White rabbits and cynomolgus macaques to observed exposures in healthy humans, to simulate...

Journal: :Vaccine 2005
Anna K Hull Carolyn J Criscuolo Vadim Mett Herman Groen Wilma Steeman Hans Westra Gail Chapman Bart Legutki Les Baillie Vidadi Yusibov

The unpredictable nature of bio-terrorism compels us to develop medical countermeasures that will enable authorities to treat individuals exposed to agents such as anthrax. We report the feasibility of producing a protective, human-derived, monoclonal antibody directed against the protective antigen (PA) of Bacillus anthracis in plants. This was achieved by transient expression using agroinfilt...

نمودار تعداد نتایج جستجو در هر سال

با کلیک روی نمودار نتایج را به سال انتشار فیلتر کنید